Simple Summary The aim of this review is to evaluate the present status of the use of cell-
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …

Translational research of liquid biopsy is just at the edge of routine clinical application: an
emerging validity of circulating tumor DNA (ctDNA) tests suggests its use for earlier cancer …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …

Over the past decade, advances in molecular biology and genomics techniques have
revolutionized the diagnosis and treatment of cancer. The technological advances in tissue …

Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Background The field of liquid biopsies in oncology is rapidly expanding, with the
application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of …

Recently, many genome‐wide profiling studies provided insights into the molecular make‐
up of major cancer types. The deeper understanding of these genetic alterations and their …

Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the
heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …

There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …

Circulating tumor DNA (ctDNA) has garnered much excitement over the past few years for its
potential clinical utility as a surrogate for tumor biopsies in early cancer detection and …